SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSabien Tech. Regulatory News (SNT)

Share Price Information for Sabien Tech. (SNT)

Share Price is delayed by 15 minutes
Get Live Data
3.75    0.00 (0.00%)
Bid:
0.00
Ask:
0.00
Spread: 0.50 (14.286%)
Market Cap: £1.19m
SNT Live PriceLast checked at - London Stock Exchange

Intraday Sabien Tech. Share Chart

Loan Agreement

7 Aug 2009 11:32

RNS Number : 0794X
Sabien Technology Group PLC
07 August 2009
 



7 August 2009

Sabien Technology Group Plc

("Sabien" or "the Company")

General Capital's Loan Agreement and Shareholdings in the Company

Introduction

Sabien is pleased to announce that it has entered into a £400,000 loan agreement ("the Loan Agreement") with TVI 2 Limited ("TV2"), a company incorporated and registered in Jersey which is advised by Thames Valley Capital Limited and which is owned by Bruce Gordon. The purpose of the Loan Agreement is to finance the repayment of Sabien's existing secured convertible loan from General Capital Venture Finance Limited ("General Capital") which was originally repayable in December 2009. 

In addition, Sabien has been notified that TV2 has bought from General Capital 3,000,000 Sabien ordinary shares, representing 11.29 per cent of the issued share capital of Sabien. General Capital has security over a further 500,000 Sabien ordinary shares as collateral over a loan made to a third party, representing 1.88 per cent of the issued share capital of Sabien, but has granted TV2 a right of first refusal to buy these shares should it take possession of these and decide to dispose of them within the next twelve months.

Details of the transaction

The Loan Agreement will have an initial term of six months and will be extendable by Sabien for a further period of 18 months. If the loan is extended, then Sabien will incur a premium of £85,000 which will be added to the new loan. The new loan will be secured by a fixed and floating charge over the assets of all the companies in the Sabien group of companies. A fixed interest rate of 8 per cent. per annum will be payable quarterly in arrears from the date of completion. Sabien will have the right to make repayments of the new loan at any time without penalty.

It is proposed that during the first six months of the Loan Agreement, Bruce Gordon will attend Sabien's Board meetings as an observer. Sabien has agreed to pay a monitoring fee of £2,000 per month while the loan is outstanding and such fee will be waived if Sabien appoints a Non Executive Director who is approved by TV2.

In addition the Company has issued TV2 with warrants to subscribe for 2,952,279 Sabien ordinary shares representing 10% of the enlarged share capital of the Company at an exercise price of 6.6 pence (subject to certain adjustments) per ordinary share ("the Warrants"). The exercise price represents a premium of 14.78% to the average mid market price of a Sabien ordinary share during the 30 trading day period of the London Stock Exchange ending on 31 July 2009 of 5.75 pence. 

The Warrants are exercisable as to 75%, at any time following the date falling 6 months from the date of issue of the Warrants with the remaining 25% being exercisable after 9 months. The Warrants will lapse to the extent not exercised by the fifth anniversary of the date of issue. 

In the event that Sabien repays the new loan by 7 February 2010, then Warrants to subscribe for 1,476,140 ordinary shares representing 50% of the Warrants and 5% of the enlarged share capital of the Company will be cancelled. 

If Sabien repays the new loan together with the repayment premium and all accrued interest on the new loan after 7 February 2010 but before 7 May 2010, then Warrants to subscribe for 738,070 ordinary shares representing 25% of the Warrants and 2.5% of the enlarged share capital of the Company will be cancelled. 

Bruce Gordon 

From 2001 to 2008 he was a senior partner of Deloitte LLP responsible for the southern region. His clients included a number of FTSE100 and FTSE350 companies. He was a member of the UK board of partners and served on various board committees. Prior to joining Deloitte in 2001 he was the UK regional managing partner at Arthur Andersen. He is the founder of Thames Valley Capital Limited, a company which advises venture capital funds.

RELATED PARTY TRANSACTION

General Capital is a substantial shareholder (as defined in the AIM Rules) of the Company. Accordingly, the early repayment of the existing loan from General Capital will be classified as a transaction with a related party for the purposes of the AIM Rules ("the Related Party Transaction"). In accordance, therefore, with the AIM Rules, the directors of the Company, having consulted with the Company's nominated adviser, Arbuthnot Securities Limited, consider that the terms of the Related Party Transaction are fair and reasonable insofar as the Company's shareholders are concerned.

Alan O'Brien, Chief Executive Officer, said:

"I am delighted to have been able to repay General Capital's convertible loan early and enter into a new and extended loan with TV2. This refinancing provides certainty of loan finance to the Company for the next two years. I am also pleased that the purchase by TV2 of the majority of General Capital's shares in Sabien puts these shares in the hands of an investor with a long term view. I look forward to working with Bruce in the future development of Sabien."

For further information:

Sabien Technology Group plc

Alan O'Brien - Chief Executive Officer

Gus Orchard - Finance Director

020 7993 3700

Arbuthnot Securities

Antonio Bossi

020 7012 2000

 

About Sabien

Sabien Technology Group (AIM: SNT) is focused on the manufacture and sale of M2G and M3G energy saving devices which are proven to reduce energy consumption on commercial boilers and air conditioning units by up to 35% with typical pay back in less than two years.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCUBORRKARWRAR
Date   Source Headline
11th Jun 20267:00 amRNSIssue of shares to directors & broker
2nd Jun 20267:00 amRNSProposed balance sheet strengthening & M2G update
29th May 20265:00 pmRNSTotal Voting Rights
21st May 20267:00 amRNSProposed Commercial Partnership & Investment
20th May 20266:22 pmRNSSettlement of Historical Contract
31st Mar 20267:00 amRNSHalf-year Report for the 6 months to 31 Dec 2025
10th Feb 20267:00 amRNSDirector/PDMR Shareholding
16th Jan 20265:30 pmRNSHolding(s) in Company
22nd Dec 202512:02 pmRNSUpdate on Funding and Strategic Arrangements
22nd Dec 202512:02 pmRNSUpdate on Funding and Strategic Arrangements
9th Dec 20251:20 pmRNSResult of Annual General Meeting
9th Dec 20257:00 amRNSAGM Statement & Trading Update
19th Nov 20257:00 amRNSProposed Strategic Agreement with COF
13th Nov 20257:00 amRNSFinal Results for the Year Ended 30 June 2025
10th Nov 20257:00 amRNSNew Factoring Facility
5th Nov 202512:01 pmRNSAppointment of Corporate Broker
2nd Oct 202512:06 pmRNSFurther update on Sabien, b.grn & related matters
19th Sep 20257:00 amRNSTrading Update
31st Jul 20254:59 pmRNSTotal Voting Rights
8th Jul 20257:00 amRNSYear End Trading Update
30th Jun 20252:53 pmRNSIssue of shares to directors
23rd Jun 20254:28 pmRNSHolding(s) in Company
17th Mar 20257:00 amRNSHalf-year Report for the 6 months to 31 Dec 2024
6th Feb 202511:43 amRNSUpdate in relation to Aeristech Limited
27th Jan 20257:00 amRNSTrading update - acceleration of new M2G orders
31st Dec 202412:30 pmRNSTotal Voting Rights
19th Dec 202410:51 amRNSResult of Annual General Meeting
19th Dec 20247:00 amRNSUpdate on US Waste Plastics to Oil Project
28th Nov 20247:00 amRNSDirector/PDMR Shareholding
19th Nov 20247:00 amRNSIssue of shares to non-executive directors
18th Nov 20247:00 amRNSFinal Results & Annual Report & Accounts for 2024
11th Nov 20247:00 amRNSNew M2G Cloud Connection System Order
17th Oct 20247:00 amRNSUpdate on US Waste Plastics to Oil Project
30th Sep 20245:00 pmRNSTotal Voting Rights
26th Sep 20244:21 pmRNSDirector/PDMR Shareholding
19th Sep 20241:00 pmRNSHolding(s) in Company
4th Sep 20245:30 pmRNSAdmission of New Shares & Total Voting Rights
29th Aug 20244:00 pmRNSUpdate on Admission of New Ordinary Shares
20th Aug 20247:00 amRNSRelated Party Funding
8th Jul 20248:15 amRNSTrading Statement
28th Mar 20242:30 pmRNSDirector/PDMR Shareholding
8th Mar 20247:00 amRNSHolding(s) in Company
6th Mar 20247:00 amRNSHolding(s) in Company
5th Mar 202411:52 amRNSHolding(s) in Company
29th Feb 20245:00 pmRNSTotal Voting Rights
21st Feb 202411:27 amRNSResult of Broker Option, Issue of Equity and TVR
20th Feb 20243:45 pmRNSDirector/PDMR Shareholding
19th Feb 20247:45 amRNSPlacement and Broker Option
19th Feb 20247:30 amRNSHalf-year Report for the 6 months to 31 Dec 2023
7th Feb 20247:00 amRNSNew system installed at Hampton Court Palace

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.